A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Description

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Conditions

Relapsing Multiple Sclerosis, Multiple Sclerosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Condition
Relapsing Multiple Sclerosis
Intervention / Treatment

-

Contacts and Locations

Birmingham

TG Therapeutics Investigational Trial Site, Birmingham, Alabama, United States, 35209

Gilbert

TG Therapeutics Investigational Trial Site, Gilbert, Arizona, United States, 85297

Phoenix

TG Therapeutics Investigational Trial Site, Phoenix, Arizona, United States, 85032

Newport Beach

TG Therapeutics Investigational Trial Site, Newport Beach, California, United States, 92663

Denver

TG Therapeutics Investigational Trial Site, Denver, Colorado, United States, 80222

Fort Collins

TG Therapeutics Investigational Trial Site, Fort Collins, Colorado, United States, 80528

Farmington

TG Therapeutics Investigational Trial Site, Farmington, Connecticut, United States, 06032

Clearwater

TG Therapeutics Investigational Trial Site, Clearwater, Florida, United States, 33761

Atlanta

TG Therapeutics Investigational Trial Site, Atlanta, Georgia, United States, 30309

Atlanta

TG Therapeutics Investigational Trial Site, Atlanta, Georgia, United States, 30327

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Confirmed Multiple Sclerosis (MS) diagnosis.
  • 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.
  • 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
  • 2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
  • 3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

TG Therapeutics, Inc.,

Study Record Dates

2027-07-01